REALISTIC: A Phase I, Dose Escalation Trial Of Recombinant Listeria Monocytogenes (Lm)-Based Vaccine Encoding Human Papilloma Virus Genotype 16 Target Antigens (ADXS11-001) In Patients With HPV-16 +ve Oropharyngeal Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Axalimogene filolisbac (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms REALISTIC
- 04 Apr 2016 Status changed to discontinued as per ISRCTN: Current Controlled Trials.
- 04 Dec 2013 Accrual to date is 5% according to United Kingdom Clinical Research Network record.
- 13 Nov 2013 Accrual to date is 2% according to United Kingdom Clinical Research Network record.